A study published in eClinicalMedicine found that for patients with heart failure and type 2 diabetes, dapagliflozin does not reduce urinary albumin-to-creatinine ratio (UACR), but it does reduce some cardiovascular events. The multicenter, randomized trial enrolled patients at 18 medical facilities in Japan and found that dapagliflozin did not significantly decrease the UACR. However, patients taking dapagliflozin did experience a larger decrease in left ventricular end-diastolic dimensions and had a lower frequency of the composite endpoint compared to a control group. The study was partially funded by biopharmaceutical companies.
Source link
Dapagliflozin cuts cardiovascular events in patients with heart failure, T2D
